The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The United States diabetes market reached a value of US$ 49.4 Billion in 2019. Looking forward, IMARC Group expects the market to exhibit moderate growth during 2020-2025. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use industries. These insights are included in the report as a major market contributor.
Diabetes, also referred to as diabetes mellitus, is a group of metabolic diseases in which a person suffers from high blood glucose. This can be either caused by the inappropriate response to insulin by the body, inadequate insulin production. If not monitored properly, diabetes can be fatal and cause serious health complications such as heart diseases, stroke, amputation, blindness and kidney diseases. According to the Centers for Disease Control and Prevention (CDC), more than 30 million adults have been diagnosed with diabetes or prediabetes in the United States. In 2018, the United States represented the third largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels. Apart from this, physical inactivity and unhealthy lifestyle have further contributed to the escalating diabetic population.
The increasing diabetes prevalence has led the Government of US to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior amongst the citizens. In line with this, there has been a rise in diabetes diagnosis, monitoring and drug treatment rates. Moreover, the FDA has approved the production of Basaglar and Admelog, the biosimilar versions of insulin glargine and lispro. Several other diabetes drugs are also expected to gain approval in the coming years, which will further drive the growth of the market. Apart from this, rapid technological advancements have enabled the manufacturers to develop continuous glucose monitoring (CGM) device. It allows type-2 diabetes patients to check their blood periodically with the help of testing strips and easily monitor their blood sugar levels.
IMARC Group provides an analysis of the key trends in each sub-segment of the United States diabetes market, along with forecasts from 2020-2025. Our report has categorized the market based on segment.
Breakup by Segment:
At present, insulin exhibits a clear dominance over oral antidiabetics on account of the convenience and efficacy of insulin delivery devices. Amongst the various product types, long acting insulin represents the largest insulin class in the US, whereas DPP-IV inhibitors are the leading oral-antidiabetics class in the nation.
The report has examined the competitive landscape of the market and finds that it is highly fragmented in nature with the presence of numerous small and large manufacturers. Some of the key players operating in the market are:
What we have achieved in this report:
Comprehensive situation analysis of the US diabetes epidemiology and its dynamics:
Focus of the Analysis:
Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:
Focus of the Analysis:
Comprehensive situation analysis of the US Insulin market and its dynamics:
Focus of the Analysis:
Infantile Spasms Therapeutics Market by Therapeutic Class (Anticonvulsants, Corticosteroids, and Others), Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others (Phase III)), Dosage (Solid, Liquid), Route of Administration (Oral, Parenteral, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Hospitals, Clinics, and Others), and Region 2023-2028
Hyperphosphatemia Drugs Market by Product (Sevelamer, Calcium Based Phosphate Binders, Iron Based Phosphate Binders, Lanthanum Carbonate, and Others), Dosage Form (Tablets, Syrups, Capsules), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Urology Robotic Surgery Market by Component (Robotic Surgery Systems, Instruments and Accessories, Services), Application (Robotic Prostatectomy, Robotic Cystectomy, Robotic Pyeloplasty, Robotic Nephrectomy, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at